What Is The Long-Term Forecast For The Global Gene-Editing Transfection Chemicals Market Growing At 7.8% CAGR?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Predicted Market Size Of The Gene-Editing Transfection Chemicals Industry By 2029?
The market size for gene-editing transfection chemicals has seen robust growth in the past few years. The market value is projected to increase from $0.99 billion in 2024 to $1.07 billion in 2025, with a compound annual growth rate (CAGR) of 8.0%. The increase during the historic period is linked to the early use of CRISPR-Cas9 systems and a rising focus on cancer and genetic disorder research. Other contributing factors include initial demand from academic and research entities, availability of rudimentary chemical transfection reagents, and the swift advancement of cell biology and molecular diagnostics.
The market for gene-editing transfection chemicals is set to experience substantial growth in the coming years, reaching a total value of $1.45 billion in 2029, indicative of a compound annual growth rate (CAGR) of 7.8%. Several factors are driving this growth during the forecast period, such as the increasing application of gene editing in clinical treatments, the broadening investments in biotechnology and pharmaceuticals, the surging demand for non-viral delivery systems, a rising incidence of rare and inherited disorders, a worldwide focus on personalized medicine, and an increase in regenerative treatments. Notable trends anticipated during this period encompass a move towards nanoparticle and lipid-based delivery, increased adoption of automation and high-throughput platforms, the appearance of microfluidic and single-cell delivery systems, the incorporation of nanotechnology, and the development of core-shell silica nanoparticle systems.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25770&type=smp
Which Factors Are Steering Growth In The Gene-Editing Transfection Chemicals Market?
The advancement of gene therapy research is predicted to stimulate the expansion of the gene-editing transfection chemicals market. Gene therapy, a method that aims to cure or avert diseases by directly altering or rectifying faulty genes within an individual’s cells, is seeing rapid research developments driven by advancements in gene-editing technologies like CRISPR. This enables scientists to accurately target and amend defective genes causing genetic disorders. The essential role of gene-editing transfection chemicals is in gene therapy research and development, facilitating the effective delivery of genetic components such as CRISPR-Cas9, mRNA and plasmid DNA into human cells. As an illustration, in August 2024, PartnerRe, an insurance company based in Switzerland, stated that by the close of 2023, the FDA had endorsed 7 gene therapies, and 2024 is on set to establish a new record with an additional seven approvals in just the first half of the year. At present, over 500 gene therapies are under development, and it is anticipated that the FDA will approve an extra 10 to 20 gene and cell therapies by 2025. Hence, the rapid development in gene therapy research is fueling the expansion of the gene-editing transfection chemicals market.
Which Segment Accounts For The Largest Share In The Gene-Editing Transfection Chemicals Market?
The gene-editing transfection chemicals market covered in this report is segmented –
1) By Chemical Type: Lipid-Based, Polymer-Based, Peptide-Based, Other Chemical Types
2) By Delivery Mechanism: Non-Viral, Viral
3) By Application: Biomedical Research, Drug Discovery, Disease Modeling, Agricultural Biotechnology, Vaccine Development, Other Applications
4) By End-User: Academic And Research Institutes, Biotechnology Companies, Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Lipid-Based: Cationic Lipids, Neutral Lipids, Ionizable Lipids
2) By Polymer-Based: Polyethyleneimine (PEI), Poly(L-Lysine) (PLL), Dendrimers
3) By Peptide-Based: Cell-Penetrating Peptides (CPPs), Amphipathic Peptides, Targeting Peptides
4) By Other Chemical Types: Inorganic Nanoparticles, Hybrid Nanoparticles
Which Long-Term Trends Will Play A Crucial Role In The Gene-Editing Transfection Chemicals Market?
Presenting innovative solutions, like lipid nanoparticle (LNP) starter kits, is becoming a focus for key players in the gene-editing transfection chemicals market. These are intended to simplify the workflows of gene therapy and mRNA delivery. LNP starter kits are essentially ready-made formulations or toolkits, each including pre-optimised lipid components and associated procedures for easier development and testing of LNP-based delivery mechanisms. For instance, in February 2024, CordenPharma, a pharmaceutical firm based in Switzerland, introduced their Lipid NanoParticle (LNP) Starter Kits. These kits are specifically designed to assist researchers and developers in creating and finetuning mRNA-based therapeutics like vaccines and gene therapies. Each kit includes four main lipids – ionizable lipids, helper lipids, sterols, and PEGylated lipids. These were taken from commercial-scale, ultra-pure materials to guarantee constant batch-to-batch quality and limit the chance of losing valuable payloads throughout the development process. CordenPharma’s purpose in offering a trustworthy and scalable lipid platform is to hasten the process of gene editing and mRNA therapeutic development and to protect highly valuable genetic payloads.
Who Are The Dominant Players In The Gene-Editing Transfection Chemicals Market Today?
Major companies operating in the gene-editing transfection chemicals market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, Integrated DNA Technologies Inc., Promega Corporation, Eurogentec S.A., Horizon Discovery Group plc, OriGene Technologies Inc., Enzo Life Sciences Inc., Apollo Scientific Ltd., Mirus Bio LLC, OZ Biosciences SAS, Genlantis Inc., Polyplus-Transfection SA, Altogen Biosystems LLC, Canvax Biotech S.L., EZ Biosystems LLC, SignaGen Laboratories.
Access The Complete Report Here:
What Regional Factors Are Accelerating Growth In The Gene-Editing Transfection Chemicals Market?
North America was the largest region in the gene-editing transfection chemicals market in 2024. The regions covered in the gene-editing transfection chemicals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25770&type=smp
Browse Through More Reports Similar to the Global Gene-Editing Transfection Chemicals Market 2025, By The Business Research Company
Genes Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Gene Synthesis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gene-synthesis-global-market-report
Nucleic Acid Based Gene Therapy Global Market Report 2025
About The Business Research Company:
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
